NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 5,270,845 Shares

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 5,270,845 shares of NeuroPace stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total value of $49,545,943.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NeuroPace Stock Performance

Shares of NASDAQ NPCE opened at $14.23 on Friday. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. NeuroPace, Inc. has a 12-month low of $5.45 and a 12-month high of $17.47. The firm’s 50-day simple moving average is $12.43 and its 200 day simple moving average is $9.38.

Wall Street Analysts Forecast Growth

NPCE has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. increased their target price on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. UBS Group assumed coverage on shares of NeuroPace in a report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective for the company. Finally, Wells Fargo & Company boosted their target price on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, NeuroPace has a consensus rating of “Moderate Buy” and an average price target of $14.80.

Hedge Funds Weigh In On NeuroPace

A number of large investors have recently modified their holdings of NPCE. Two Sigma Advisers LP bought a new position in NeuroPace in the 4th quarter worth approximately $117,000. Two Sigma Investments LP acquired a new stake in shares of NeuroPace in the 4th quarter valued at $293,000. Point72 Asset Management L.P. bought a new stake in shares of NeuroPace during the fourth quarter worth $369,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of NeuroPace during the fourth quarter valued at $639,000. Finally, Cubist Systematic Strategies LLC bought a new position in NeuroPace in the fourth quarter valued at about $112,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.